176 related articles for article (PubMed ID: 25518344)
1. [Antisense oligodeoxynucleotide therapy for castration-resistant prostate cancer].
Miyake H; Fujisawa M
Nihon Rinsho; 2014 Dec; 72(12):2121-5. PubMed ID: 25518344
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic.
Miyake H; Hara I; Gleave ME
Int J Urol; 2005 Sep; 12(9):785-94. PubMed ID: 16201973
[TBL] [Abstract][Full Text] [Related]
3. Antisense oligodeoxynucleotide therapy for bladder cancer: recent advances and future prospects.
Miyake H; Hara I; Fujisaw M; Gleave ME
Expert Rev Anticancer Ther; 2005 Dec; 5(6):1001-9. PubMed ID: 16336091
[TBL] [Abstract][Full Text] [Related]
4. [Antisese oligonucleotide therapy for patients with castration-resistant prostate cancer].
Muramaki M; Miyake H; Fujisawa M
Nihon Rinsho; 2016 May; 74 Suppl 3():234-7. PubMed ID: 27344734
[No Abstract] [Full Text] [Related]
5. The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer.
Miyake H; Hara I; Fujisawa M; Gleave ME
Expert Opin Investig Drugs; 2006 May; 15(5):507-17. PubMed ID: 16634689
[TBL] [Abstract][Full Text] [Related]
6. [Gene therapy for castration resistant prostate cancer].
Nasu Y
Nihon Rinsho; 2014 Dec; 72(12):2152-7. PubMed ID: 25518350
[TBL] [Abstract][Full Text] [Related]
7. Lipid-oligonucleotide conjugates improve cellular uptake and efficiency of TCTP-antisense in castration-resistant prostate cancer.
Karaki S; Benizri S; Mejías R; Baylot V; Branger N; Nguyen T; Vialet B; Oumzil K; Barthélémy P; Rocchi P
J Control Release; 2017 Jul; 258():1-9. PubMed ID: 28472637
[TBL] [Abstract][Full Text] [Related]
8. Antisense therapy in malignant diseases: status quo and quo vadis?
Tamm I
Clin Sci (Lond); 2006 Apr; 110(4):427-42. PubMed ID: 16526947
[TBL] [Abstract][Full Text] [Related]
9. Molecular landscape of prostate cancer: implications for current clinical trials.
Khemlina G; Ikeda S; Kurzrock R
Cancer Treat Rev; 2015 Nov; 41(9):761-6. PubMed ID: 26210103
[TBL] [Abstract][Full Text] [Related]
10. Molecular alterations and emerging targets in castration resistant prostate cancer.
Lorente D; De Bono JS
Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
[TBL] [Abstract][Full Text] [Related]
11. DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer.
Le TK; Cherif C; Omabe K; Paris C; Lannes F; Audebert S; Baudelet E; Hamimed M; Barbolosi D; Finetti P; Bastide C; Fazli L; Gleave M; Bertucci F; Taïeb D; Rocchi P
Mol Ther; 2023 Feb; 31(2):471-486. PubMed ID: 35965411
[TBL] [Abstract][Full Text] [Related]
12. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
Miyake H; Nelson C; Rennie PS; Gleave ME
Cancer Res; 2000 May; 60(9):2547-54. PubMed ID: 10811138
[TBL] [Abstract][Full Text] [Related]
13. [Prospects for antisense therapy].
Maekawa T
Rinsho Ketsueki; 1995 May; 36(5):410-8. PubMed ID: 7783344
[TBL] [Abstract][Full Text] [Related]
14. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in prostate cancer: challenges and opportunities.
Noguchi M; Koga N; Moriya F; Itoh K
Immunotherapy; 2016; 8(1):69-77. PubMed ID: 26642100
[TBL] [Abstract][Full Text] [Related]
16. TCTP Has a Crucial Role in the Different Stages of Prostate Cancer Malignant Progression.
Baylot V; Karaki S; Rocchi P
Results Probl Cell Differ; 2017; 64():255-261. PubMed ID: 29149413
[TBL] [Abstract][Full Text] [Related]
17. Current, new and novel therapy for castration-resistant prostate cancer.
Gaya JM; Ahallal Y; Sanchez-Salas R; Barret E; Rozet F; Galiano M; Macek P; Durand M; Cerruti J; Prapotnich D; Ropert S; Bennamoun M; Cathelineau X
Expert Rev Anticancer Ther; 2013 Jul; 13(7):819-27. PubMed ID: 23875660
[TBL] [Abstract][Full Text] [Related]
18. [New era of the treatment of CRPC in Japan].
Akaza H
Gan To Kagaku Ryoho; 2014 Jul; 41(7):804. PubMed ID: 25131863
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor co-regulatory networks in castration-resistant prostate cancer.
Sung YY; Cheung E
Endocr Relat Cancer; 2014 Feb; 21(1):R1-R11. PubMed ID: 24152433
[TBL] [Abstract][Full Text] [Related]
20. Enhanced radiosensitivity by inhibition of the anti-apoptotic gene clusterin using antisense oligodeoxynucleotide in a human bladder cancer model.
Yamanaka K; Gleave M; Muramaki M; Hara I; Miyake H
Oncol Rep; 2005 May; 13(5):885-90. PubMed ID: 15809754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
